Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
This article was originally published in The Pink Sheet Daily
Executive Summary
Already holding worldwide rights to the oral formulation and rest-of-world rights to intravenous vernakalant, Merck will partner with Cardiome Pharma to obtain FDA approval of IV vernakalant.